Skip to main content
Top
Published in: Digestive Diseases and Sciences 6/2021

01-06-2021 | Endoscopy | Original Article

A Novel Score to Predict Esophageal Varices in Patients with Compensated Advanced Chronic Liver Disease

Authors: Vikram Kotwal, Chimezie Mbachi, Yuchen Wang, Bashar Attar, Tejinder Randhawa, Estefania Flores, Julian Robles, Craig Rosenstengle, Melchor Demetria, Oluwatoyin Adeyemi, Gregory Huhn, Arvind R. Murali

Published in: Digestive Diseases and Sciences | Issue 6/2021

Login to get access

Abstract

Background and Aims

Several criteria have been described to noninvasively predict the presence of high-risk esophageal varices in patients with compensated advanced chronic liver disease (cACLD). However, a recent study showed that treatment with β blockers could increase decompensation-free survival in patients with clinically significant portal hypertension, thereby making it important to predict the presence of any esophageal varices. We aimed to develop a simple scoring system to predict any esophageal varices.

Methods

We retrospectively reviewed patients who had vibration-controlled transient elastography (VCTE) at Cook County Hospital, Chicago, USA. Patients with cACLD and liver stiffness measurement (LSM) ≥ 10 kPa with esophagogastroduodenoscopy performed within one year of VCTE were analyzed. We generated a novel score to predict esophageal varices, using the beta coefficient of predictive variables. The score was validated in an external cohort at the University of Iowa Hospital, USA.

Results

There were 372 patients in the development cohort and 200 patients in the validation cohort. LSM, platelet count, and albumin were identified as predictors of esophageal varices and were included for generating the Cook County score as “platelet count * − 0.0155872 + VCTE score * 0.0387052 + albumin * − 0.8549209.” The area under receiver operating curve for our score was 0.86 for any varices and 0.85 for high risk varices and avoided more endoscopies than the expanded Baveno VI criteria while maintaining a very low miss rate (negative predictive value > 99%).

Conclusion

We propose a new, highly accurate, and easy-to-use scoring system to predict the presence of not only high-risk but any esophageal varices in patients with cACLD.
Literature
1.
go back to reference de Franchis R, Baveno VIF. Expanding consensus in portal hypertension: report of the Baveno VI consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63:743–752.CrossRef de Franchis R, Baveno VIF. Expanding consensus in portal hypertension: report of the Baveno VI consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63:743–752.CrossRef
2.
go back to reference Maurice JB, Brodkin E, Arnold F, et al. Validation of the Baveno VI criteria to identify low risk cirrhotic patients not requiring endoscopic surveillance for varices. J Hepatol. 2016;65:899–905.CrossRef Maurice JB, Brodkin E, Arnold F, et al. Validation of the Baveno VI criteria to identify low risk cirrhotic patients not requiring endoscopic surveillance for varices. J Hepatol. 2016;65:899–905.CrossRef
3.
go back to reference Jangouk P, Turco L, De Oliveira A, Schepis F, Villa E, Garcia-Tsao G. Validating, deconstructing and refining Baveno criteria for ruling out high-risk varices in patients with compensated cirrhosis. Liver Int Off J Int Assoc Study Liver. 2017;37:1177–1183. Jangouk P, Turco L, De Oliveira A, Schepis F, Villa E, Garcia-Tsao G. Validating, deconstructing and refining Baveno criteria for ruling out high-risk varices in patients with compensated cirrhosis. Liver Int Off J Int Assoc Study Liver. 2017;37:1177–1183.
4.
go back to reference Llop E, Lopez M, de la Revilla J, et al. Validation of noninvasive methods to predict the presence of gastroesophageal varices in a cohort of patients with compensated advanced chronic liver disease. J Gastroenterol Hepatol. 2017;32:1867–1872.CrossRef Llop E, Lopez M, de la Revilla J, et al. Validation of noninvasive methods to predict the presence of gastroesophageal varices in a cohort of patients with compensated advanced chronic liver disease. J Gastroenterol Hepatol. 2017;32:1867–1872.CrossRef
5.
go back to reference Bae J, Sinn DH, Kang W, et al. Validation of the Baveno VI and the expanded Baveno VI criteria to identify patients who could avoid screening endoscopy. Liver Int Off J Int Assoc Study Liver. 2018;38:1442–1448. Bae J, Sinn DH, Kang W, et al. Validation of the Baveno VI and the expanded Baveno VI criteria to identify patients who could avoid screening endoscopy. Liver Int Off J Int Assoc Study Liver. 2018;38:1442–1448.
6.
go back to reference Thabut D, Bureau C, Layese R, Bourcier V, Hammouche M, Cagnot C, et al. Validation of Baveno VI criteria for screening and surveillance of esophageal varices in patients with compensated cirrhosis and a sustained response to antiviral therapy. Gastroenterology. 2019;156:997–1009e5. Thabut D, Bureau C, Layese R, Bourcier V, Hammouche M, Cagnot C, et al. Validation of Baveno VI criteria for screening and surveillance of esophageal varices in patients with compensated cirrhosis and a sustained response to antiviral therapy. Gastroenterology. 2019;156:997–1009e5.
7.
go back to reference Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017;65:310–335.CrossRef Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017;65:310–335.CrossRef
8.
go back to reference Augustin S, Pons M, Maurice JB, et al. Expanding the Baveno VI criteria for the screening of varices in patients with compensated advanced chronic liver disease. Hepatology. 2017;66:1980–1988.CrossRef Augustin S, Pons M, Maurice JB, et al. Expanding the Baveno VI criteria for the screening of varices in patients with compensated advanced chronic liver disease. Hepatology. 2017;66:1980–1988.CrossRef
9.
go back to reference Tosetti G, Primignani M, La Mura V, et al. Evaluation of three “beyond Baveno VI” criteria to safely spare endoscopies in compensated advanced chronic liver disease. Dig Liver Dis.. 2019;51:1135–1140.CrossRef Tosetti G, Primignani M, La Mura V, et al. Evaluation of three “beyond Baveno VI” criteria to safely spare endoscopies in compensated advanced chronic liver disease. Dig Liver Dis.. 2019;51:1135–1140.CrossRef
10.
go back to reference Calvaruso V, Cacciola I, Licata A, et al. Is transient elastography needed for noninvasive assessment of high-risk varices? The REAL experience. Am J Gastroenterol. 2019;114:1275–1282.CrossRef Calvaruso V, Cacciola I, Licata A, et al. Is transient elastography needed for noninvasive assessment of high-risk varices? The REAL experience. Am J Gastroenterol. 2019;114:1275–1282.CrossRef
11.
go back to reference Moctezuma-Velazquez C, Saffioti F, Tasayco-Huaman S, et al. Non-invasive prediction of high-risk varices in patients with primary biliary cholangitis and primary sclerosing cholangitis. Am J Gastroenterol. 2019;114:446–452.CrossRef Moctezuma-Velazquez C, Saffioti F, Tasayco-Huaman S, et al. Non-invasive prediction of high-risk varices in patients with primary biliary cholangitis and primary sclerosing cholangitis. Am J Gastroenterol. 2019;114:446–452.CrossRef
12.
go back to reference Stafylidou M, Paschos P, Katsoula A, et al. Performance of Baveno VI and expanded Baveno VI criteria for excluding high-risk varices in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019;17:1744–1755.CrossRef Stafylidou M, Paschos P, Katsoula A, et al. Performance of Baveno VI and expanded Baveno VI criteria for excluding high-risk varices in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019;17:1744–1755.CrossRef
13.
go back to reference D’Amico G, Pasta L, Morabito A, et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Aliment Pharmacol Ther. 2014;39:1180–1193.CrossRef D’Amico G, Pasta L, Morabito A, et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Aliment Pharmacol Ther. 2014;39:1180–1193.CrossRef
14.
go back to reference Villanueva C, Albillos A, Genesca J, et al. beta blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2019;393:1597–1608.CrossRef Villanueva C, Albillos A, Genesca J, et al. beta blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2019;393:1597–1608.CrossRef
15.
go back to reference Dong TS, Kalani A, Aby ES, et al. Machine learning-based development and validation of a scoring system for screening high-risk esophageal varices. Clin Gastroenterol Hepatol. 2019;17:1894–1901e1.CrossRef Dong TS, Kalani A, Aby ES, et al. Machine learning-based development and validation of a scoring system for screening high-risk esophageal varices. Clin Gastroenterol Hepatol. 2019;17:1894–1901e1.CrossRef
Metadata
Title
A Novel Score to Predict Esophageal Varices in Patients with Compensated Advanced Chronic Liver Disease
Authors
Vikram Kotwal
Chimezie Mbachi
Yuchen Wang
Bashar Attar
Tejinder Randhawa
Estefania Flores
Julian Robles
Craig Rosenstengle
Melchor Demetria
Oluwatoyin Adeyemi
Gregory Huhn
Arvind R. Murali
Publication date
01-06-2021
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 6/2021
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-020-06456-3

Other articles of this Issue 6/2021

Digestive Diseases and Sciences 6/2021 Go to the issue

DDS AUTHOR PROFILES

Author Spotlight: Yejoo Jeon

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine